BRPI0410785A - molécula de ácido nucleico isolada, célula hospedeira, animal transgênico não humano, proteìna isolada, oligonucleotìdeo anti-sentido, molécula de sirna, anticorpo isolado, métodos de triagem quanto aos compostos de teste capazes de inibir, de intensificar ou imitar a interação do gitrl com o gitr, para diagnosticar doenças, para tratar um paciente em risco ou diagnosticado com uma doença, para induzir e para inibir a proliferação de uma população celular contendo células t efetoras, de bloquear a supressão e de supressão de uma população celular que inclua células t efetoras na presença de células t reguladoras cd4+cd25+, e para tratar uma doença, composição farmacêutica, e, adjuvante de vacina - Google Patents

molécula de ácido nucleico isolada, célula hospedeira, animal transgênico não humano, proteìna isolada, oligonucleotìdeo anti-sentido, molécula de sirna, anticorpo isolado, métodos de triagem quanto aos compostos de teste capazes de inibir, de intensificar ou imitar a interação do gitrl com o gitr, para diagnosticar doenças, para tratar um paciente em risco ou diagnosticado com uma doença, para induzir e para inibir a proliferação de uma população celular contendo células t efetoras, de bloquear a supressão e de supressão de uma população celular que inclua células t efetoras na presença de células t reguladoras cd4+cd25+, e para tratar uma doença, composição farmacêutica, e, adjuvante de vacina

Info

Publication number
BRPI0410785A
BRPI0410785A BRPI0410785-3A BRPI0410785A BRPI0410785A BR PI0410785 A BRPI0410785 A BR PI0410785A BR PI0410785 A BRPI0410785 A BR PI0410785A BR PI0410785 A BRPI0410785 A BR PI0410785A
Authority
BR
Brazil
Prior art keywords
disease
cells
treat
isolated
suppression
Prior art date
Application number
BRPI0410785-3A
Other languages
English (en)
Inventor
Mary Collins
Ethan Menahem Shevach
Rebecca Suzanne Mchugh
James Matthew Whitters
Deborah Ann Young
Michael Chapman Byrne
Padmalatha S Reddy
Geoffrey Laurence Stephens
Beatriz M Carreno
Original Assignee
Wyeth Corp
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Us Gov Health & Human Serv filed Critical Wyeth Corp
Publication of BRPI0410785A publication Critical patent/BRPI0410785A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)

Abstract

"MOLéCULA DE áCIDO NUCLEICO ISOLADA, CéLULA HOSPEDEIRA, ANIMAL TRANSGêNICO NãO HUMANO, PROTEìNA ISOLADA, OLIGONUCLEOTìDEO ANTI-SENTIDO, MOLéCULA DE SIRNA, ANTICORPO ISOLADO, MéTODOS DE TRIAGEM QUANTO AOS COMPOSTOS DE TESTE CAPAZES DE INIBIR, DE INTENSIFICAR OU IMITAR A INTERAçãO DO GITRL COM O GITR, PARA DIAGNOSTICAR DOENçAS, PARA TRATAR UM PACIENTE EM RISCO OU DIAGNOSTICADO COM UMA DOENçA, PARA INDUZIR E PARA INIBIR A PROLIFERAçãO DE UMA POPULAçãO CELULAR CONTENDO CéLULAS T EFETORAS, DE BLOQUEAR A SUPRESSãO E DE SUPRESSãO DE UMA POPULAçãO CELULAR QUE INCLUA CéLULAS T EFETORAS NA PRESENçA DE CéLULAS T REGULADORAS CD4¬ +¬CD25¬ +¬, E PARA TRATAR UMA DOENçA, COMPOSIçãO FARMACêUTICA, E, ADJUVANTE DE VACINA". A presente invenção fornece novos polinucleotídeos e polipeptídeos isolados e purificados relacionados a um novo ligando para o receptor de TNF induzido por glicocorticóides (GITR). A invenção também fornece anticorpos para o ligando de GITR (GITRL). A presente invenção também é direcionada a novos métodos para diagnosticar, prognosticar, monitorar o progresso, e tratar de distúrbios que se originam da desregulação do sistema imune (por exemplo, distúrbios autoimunes, doenças inflamatórias e rejeição de transplantes, e cânceres e doenças infecciosas) com o uso do GITRL e/ou moduladores do GITRL. A presente invenção é ainda direcionada às novas terapêuticas e alvos terapêuticos e a métodos de triagem e avaliação de compostos de testes para a intervenção (tratamento) e prevenção dos referidos distúrbios originários da desregulação do sistema imune, quando relacionados ao GITRL e ao GITR.
BRPI0410785-3A 2003-05-23 2004-05-24 molécula de ácido nucleico isolada, célula hospedeira, animal transgênico não humano, proteìna isolada, oligonucleotìdeo anti-sentido, molécula de sirna, anticorpo isolado, métodos de triagem quanto aos compostos de teste capazes de inibir, de intensificar ou imitar a interação do gitrl com o gitr, para diagnosticar doenças, para tratar um paciente em risco ou diagnosticado com uma doença, para induzir e para inibir a proliferação de uma população celular contendo células t efetoras, de bloquear a supressão e de supressão de uma população celular que inclua células t efetoras na presença de células t reguladoras cd4+cd25+, e para tratar uma doença, composição farmacêutica, e, adjuvante de vacina BRPI0410785A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47284403P 2003-05-23 2003-05-23
US54797504P 2004-02-26 2004-02-26
PCT/US2004/016381 WO2004107618A2 (en) 2003-05-23 2004-05-24 Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0410785A true BRPI0410785A (pt) 2006-06-20

Family

ID=33493329

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410785-3A BRPI0410785A (pt) 2003-05-23 2004-05-24 molécula de ácido nucleico isolada, célula hospedeira, animal transgênico não humano, proteìna isolada, oligonucleotìdeo anti-sentido, molécula de sirna, anticorpo isolado, métodos de triagem quanto aos compostos de teste capazes de inibir, de intensificar ou imitar a interação do gitrl com o gitr, para diagnosticar doenças, para tratar um paciente em risco ou diagnosticado com uma doença, para induzir e para inibir a proliferação de uma população celular contendo células t efetoras, de bloquear a supressão e de supressão de uma população celular que inclua células t efetoras na presença de células t reguladoras cd4+cd25+, e para tratar uma doença, composição farmacêutica, e, adjuvante de vacina

Country Status (13)

Country Link
US (2) US7618632B2 (pt)
EP (1) EP1631588A2 (pt)
JP (2) JP4638876B2 (pt)
KR (1) KR20060052681A (pt)
AU (1) AU2004244626A1 (pt)
BR (1) BRPI0410785A (pt)
CA (1) CA2525717A1 (pt)
CO (1) CO5680484A2 (pt)
MX (1) MXPA05012475A (pt)
NO (1) NO20055306L (pt)
NZ (1) NZ543654A (pt)
RU (1) RU2369636C2 (pt)
WO (1) WO2004107618A2 (pt)

Families Citing this family (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
US20060099171A1 (en) * 2004-11-05 2006-05-11 Masahide Tone Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
US20110212086A1 (en) * 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
KR100877978B1 (ko) * 2007-01-12 2009-01-12 가천의과학대학교 산학협력단 Ｃｄ８６ 분자가 넉 다운된 형질전환 돼지 혈관 내피세포주 및 이의 제조방법
EP2737907A3 (en) 2007-05-07 2014-11-05 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
JP5932217B2 (ja) 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Ｇｉｔｒ結合分子を使用する併用療法
US20090136446A1 (en) * 2007-11-02 2009-05-28 Ludwig Institute For Cancer Research Ltd. Induction of regulatory t cell-resistant helper cd4+ t cells
US8586023B2 (en) 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
PL2344540T3 (pl) 2008-10-02 2018-05-30 Aptevo Research And Development Llc Białka wiążące wiele celów antagonistyczne względem cd86
US8709424B2 (en) * 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
DK2477656T3 (en) 2009-09-15 2017-06-26 Csl Ltd TREATMENT OF NEUROLOGICAL CONDITIONS
GB0919054D0 (en) * 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
WO2012003810A1 (zh) * 2010-07-09 2012-01-12 中国科学院上海巴斯德研究所 Foxp3及调节性ｔ细胞的调节因子及其应用
US8440195B2 (en) 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
AU2012339618B2 (en) * 2011-11-15 2017-09-07 The Walter And Eliza Hall Institute Of Medical Research Soluble mediator
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
CN105101995A (zh) 2013-03-15 2015-11-25 宾夕法尼亚大学理事会 具有生物分子佐剂的疫苗
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
WO2015066413A1 (en) 2013-11-01 2015-05-07 Novartis Ag Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
EA201690987A1 (ru) 2013-11-13 2016-10-31 Новартис Аг Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
CA2931684C (en) 2013-12-19 2024-02-20 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015229103C9 (en) 2014-03-14 2020-11-26 Immutep S.A.S Antibody molecules to LAG-3 and uses thereof
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
EP3511328B1 (en) 2014-03-24 2021-03-03 Novartis AG Monobactam organic compounds for the treatment of bacterial infections
CA2940671A1 (en) 2014-04-07 2015-10-15 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
CN108064242B (zh) 2014-05-28 2022-10-21 阿吉纳斯公司 抗gitr抗体和其使用方法
BR112016028378A2 (pt) 2014-06-06 2017-10-24 Bristol Myers Squibb Co anticorpos contra o receptor do fator de necrose tumoral induzido por glicocorticoide (gitr) e usos dos mesmos
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
SG11201700476VA (en) 2014-07-21 2017-02-27 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
US10160726B2 (en) 2014-08-06 2018-12-25 Novartis Ag Quinolone derivatives as antibacterials
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
DK3183268T3 (da) 2014-08-19 2020-05-11 Univ Pennsylvania Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
EP3925622A1 (en) 2014-09-13 2021-12-22 Novartis AG Combination therapies
CN114621969A (zh) 2014-09-17 2022-06-14 诺华股份有限公司 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
US20170209574A1 (en) 2014-10-03 2017-07-27 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
SG11201702895SA (en) 2014-10-08 2017-05-30 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
LT3233843T (lt) 2014-12-16 2019-12-10 Novartis Ag Izoksazolo hidroksamido rūgšties junginiai, kaip lpxc inhibitoriai
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
SG11201705293WA (en) 2014-12-29 2017-07-28 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
ES2876974T3 (es) 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
AU2016249005B2 (en) 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2016196792A1 (en) 2015-06-03 2016-12-08 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
WO2017009843A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
EP3325504A1 (en) 2015-07-21 2018-05-30 Novartis AG Methods for improving the efficacy and expansion of immune cells
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
CN108780084B (zh) 2015-09-03 2022-07-22 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
JP2019500893A (ja) 2015-11-03 2019-01-17 ヤンセン バイオテツク，インコーポレーテツド Ｐｄ−１及びｔｉｍ−３に特異的に結合する抗体及びそれらの使用
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
WO2017096189A1 (en) * 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
US20180371093A1 (en) 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP3389711A1 (en) 2015-12-18 2018-10-24 Novartis AG Antibodies targeting cd32b and methods of use thereof
EP3393504A1 (en) 2015-12-22 2018-10-31 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
JP2019500874A (ja) 2015-12-28 2019-01-17 ノバルティス アーゲー キメラ抗原受容体発現細胞の作製方法
AU2017208133B2 (en) 2016-01-11 2023-12-21 Universitat Zurich Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
MX2018010010A (es) 2016-02-19 2018-11-09 Novartis Ag Compuestos tetraciclicos de piridona como antivirales.
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
CN109069638B (zh) 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
JP7005508B2 (ja) 2016-03-24 2022-01-21 ノバルティス アーゲー ヒトライノウイルスの阻害剤としてのアルキニルヌクレオシド類似体
AU2017278193B9 (en) 2016-06-10 2024-02-01 Regeneron Pharmaceuticals, Inc. Anti-GITR antibodies and uses thereof
CA3026356A1 (en) 2016-06-14 2017-12-21 Novartis Ag Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
MX2018016227A (es) 2016-06-24 2019-07-08 Infinity Pharmaceuticals Inc Terapias de combinacion.
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN109641947B (zh) 2016-07-20 2023-04-14 犹他大学研究基金会 Cd229 car t细胞及其使用方法
WO2018031258A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
US20180044430A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. FC Engineered Anti-TNFR Superfamily Member Antibodies Having Enhanced Atonistic Activity and Methods of Using Them
WO2018047109A1 (en) 2016-09-09 2018-03-15 Novartis Ag Polycyclic pyridone compounds as antivirals
AU2017332161B2 (en) 2016-09-21 2024-07-04 The United States Government As Represented By The Department Of Veterans Affairs Chimeric antigen receptor (car) that targets chemokine receptor CCR4 and its use
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
US10525083B2 (en) 2016-10-07 2020-01-07 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
TW201819380A (zh) 2016-10-18 2018-06-01 瑞士商諾華公司 作為抗病毒劑之稠合四環吡啶酮化合物
JOP20190100A1 (ar) * 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
WO2018102787A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
UA124474C2 (uk) 2016-12-22 2021-09-22 Емджен Інк. БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
EP3367098A1 (en) * 2017-02-24 2018-08-29 CeMM - Forschungszentrum für Molekulare Medizin GmbH Methods for determining interaction between biological cells
KR20200020662A (ko) 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AR111419A1 (es) 2017-04-27 2019-07-10 Novartis Ag Compuestos fusionados de indazol piridona como antivirales
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
AR111658A1 (es) 2017-05-05 2019-08-07 Novartis Ag 2-quinolinonas tricíclicas como agentes antibacteriales
KR20200006115A (ko) 2017-05-16 2020-01-17 브리스톨-마이어스 스큅 컴퍼니 항-gitr 효능제 항체에 의한 암의 치료
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
CN111344303A (zh) 2017-06-01 2020-06-26 Xencor股份有限公司 结合cd123和cd3的双特异性抗体
US11413310B2 (en) 2017-06-02 2022-08-16 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
BR112019024291A2 (pt) 2017-06-09 2020-07-28 Providence Health & Services-Oregon utilização de cd39 e de cd103 para a identificação de células t tumorais humanas reativas para o tratamento do câncer
MX2019015155A (es) 2017-06-29 2020-08-03 Juno Therapeutics Inc Modelo de raton para valorar toxicidades asociadas con inmunoterapias.
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
US20200370012A1 (en) 2017-10-25 2020-11-26 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
MA50860A (fr) 2017-11-01 2020-09-09 Juno Therapeutics Inc Récepterus chimériques d'antigène contre l'antigène de maturation des cellules b et polynucleotides codants
JP2021503458A (ja) 2017-11-17 2021-02-12 ノバルティス アーゲー 新規のジヒドロイソキサゾール化合物及びｂ型肝炎治療のためのそれらの使用
MA51210A (fr) 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
US12006356B2 (en) 2017-12-15 2024-06-11 Juno Therapeutics, Inc. Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
EP3728266A1 (en) 2017-12-20 2020-10-28 Novartis AG Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
WO2019166951A1 (en) 2018-02-28 2019-09-06 Novartis Ag Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
WO2019184909A1 (zh) 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3788038B1 (en) 2018-05-04 2023-10-11 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019213526A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
AU2019265822B2 (en) 2018-05-10 2024-07-18 Amgen Inc. KRAS G12C inhibitors for the treatment of cancer
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
AU2019278998B2 (en) 2018-06-01 2023-11-09 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JP2021525769A (ja) 2018-06-01 2021-09-27 ノバルティス アーゲー Ｃｄ１２３及びｃｄ３に結合する二重特異性抗体の投与
MA52780A (fr) 2018-06-11 2021-04-14 Amgen Inc Inhibiteurs de kras g12c pour le traitement du cancer
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
SG11202011830SA (en) 2018-06-13 2020-12-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
JP2021529556A (ja) 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドＧｅｎｓｕｎ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． 抗腫瘍アンタゴニスト
WO2020047462A2 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Methods of treating aging-related disorders
CN113365663A (zh) 2018-08-30 2021-09-07 Hcw生物科技公司 单链嵌合多肽和其用途
EP3844181A1 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
US20220364055A1 (en) 2018-08-31 2022-11-17 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
CN112823167A (zh) 2018-09-07 2021-05-18 辉瑞大药厂 抗-αvβ8抗体和组合物及其用途
KR102672512B1 (ko) 2018-09-12 2024-06-10 노파르티스 아게 항바이러스 피리도피라진디온 화합물
US20220047633A1 (en) 2018-09-28 2022-02-17 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
IL305106A (en) 2018-09-29 2023-10-01 Novartis Ag A process for producing a compound to inhibit the activity of SHP2
KR20210113169A (ko) 2018-11-01 2021-09-15 주노 쎄러퓨티크스 인코퍼레이티드 Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
MX2021005022A (es) 2018-11-01 2021-09-08 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
BR112021009420A2 (pt) 2018-11-16 2021-11-23 Juno Therapeutics Inc Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MX2021005700A (es) 2018-11-19 2021-07-07 Amgen Inc Inhibidores de kras g12c y metodos de uso de los mismos.
US20220088070A1 (en) 2018-11-30 2022-03-24 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
MA54543A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
CA3123227A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
EP3898592A1 (en) 2018-12-20 2021-10-27 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
EP3917570A1 (en) 2019-01-29 2021-12-08 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
CN113727758A (zh) 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
US20230148450A9 (en) 2019-03-01 2023-05-11 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
RU2734432C1 (ru) * 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CA3140392A1 (en) 2019-05-21 2020-11-26 Amgen Inc. Solid state forms
AU2020294797A1 (en) 2019-06-21 2021-12-23 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CN114340735A (zh) 2019-06-28 2022-04-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
CA3146693A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CA3147276A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
MX2022001181A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
CN114401953A (zh) 2019-08-02 2022-04-26 美国安进公司 Kif18a抑制剂
JP7417715B2 (ja) 2019-09-26 2024-01-18 ノバルティス アーゲー 抗ウイルスピラゾロピリジノン化合物
MX2022004656A (es) 2019-10-24 2022-05-25 Amgen Inc Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
CR20220240A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
MX2022005360A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
JP2022553858A (ja) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
BR112022008858A2 (pt) 2019-11-08 2022-09-06 Revolution Medicines Inc Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
JP2023501528A (ja) 2019-11-14 2023-01-18 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成
TW202132271A (zh) 2019-11-14 2021-09-01 美商安進公司 Ｋｒａｓ ｇ１２ｃ抑制劑化合物之改善的合成
CN114945382A (zh) 2019-11-26 2022-08-26 诺华股份有限公司 Cd19和cd22嵌合抗原受体及其用途
AR120566A1 (es) 2019-11-26 2022-02-23 Novartis Ag Receptores de antígeno quiméricos y sus usos
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
KR20220124768A (ko) 2020-01-07 2022-09-14 레볼루션 메디슨즈, 인크. Shp2 억제제 투여 및 암 치료방법
WO2021163618A1 (en) 2020-02-14 2021-08-19 Novartis Ag Method of predicting response to chimeric antigen receptor therapy
US20230119606A1 (en) * 2020-02-18 2023-04-20 Octagon Therapeutics, Inc. Immune cell modulators
CN115397460A (zh) 2020-02-27 2022-11-25 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
TW202146452A (zh) 2020-02-28 2021-12-16 瑞士商諾華公司 結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥
US11787867B2 (en) 2020-03-06 2023-10-17 Regeneron Pharmaceuticals, Inc. Anti-GITR antibodies and uses thereof
CN111218530B (zh) * 2020-03-19 2023-10-31 广西壮族自治区水产科学研究院 荧光定量pcr检测十足目虹彩病毒1的引物组及试剂盒
US20230149462A1 (en) 2020-04-10 2023-05-18 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
JPWO2021225159A1 (pt) * 2020-05-08 2021-11-11
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
KR20230042600A (ko) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
KR20230081726A (ko) 2020-09-03 2023-06-07 레볼루션 메디슨즈, 인크. Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
JP2023541916A (ja) 2020-09-15 2023-10-04 レボリューション メディシンズ インコーポレイテッド がんの治療における、ｒａｓ阻害剤としてのインドール誘導体
JP2023549504A (ja) 2020-11-13 2023-11-27 ノバルティス アーゲー キメラ抗原受容体（ｃａｒ）発現細胞との組合せ療法
US20240050432A1 (en) 2020-12-08 2024-02-15 Infinity Pharmaceuticals, Inc. Eganelisib for use in the treatment of pd-l1 negative cancer
WO2022133102A1 (en) * 2020-12-18 2022-06-23 Northwestern University Pi3k inhibitors for protection against glucocorticoid-induced atrophy
CA3203111A1 (en) 2020-12-22 2022-06-30 Kailiang Wang Sos1 inhibitors and uses thereof
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
PE20240089A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
EP4334321A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras inhibitors
TW202307210A (zh) 2021-06-01 2023-02-16 瑞士商諾華公司 Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
BR112023022097A2 (pt) 2021-06-07 2023-12-19 Agonox Inc Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CN118201914A (zh) 2021-09-08 2024-06-14 雷多纳治疗公司 Papd5和/或papd7抑制剂4-氧代-1,4-二氢喹啉-3-甲酸衍生物
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023154905A1 (en) 2022-02-14 2023-08-17 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024129778A2 (en) 2022-12-13 2024-06-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
CN116925206B (zh) * 2023-07-18 2024-04-23 湖南中晟全肽生物科技股份有限公司 Gitr相关的多肽及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) * 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6406867B1 (en) * 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
US5998171A (en) * 1996-08-16 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human endokine alpha
GB9625074D0 (en) 1996-12-02 1997-01-22 Pharmacia & Upjohn Spa Receptor belonging to the TNF/NGF receptor family
DK1032672T3 (da) * 1997-11-18 2009-04-27 Genentech Inc DNA19355-polypeptid, en tumornekrosefaktor-homolog
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6077673A (en) * 1998-03-31 2000-06-20 Clontech Laboratories, Inc. Mouse arrays and kits comprising the same
WO2003006058A1 (en) * 2001-07-12 2003-01-23 Wyeth Cd25+ differential markers and uses thereof

Also Published As

Publication number Publication date
CA2525717A1 (en) 2004-12-09
US7618632B2 (en) 2009-11-17
WO2004107618A2 (en) 2004-12-09
RU2369636C2 (ru) 2009-10-10
MXPA05012475A (es) 2006-05-25
EP1631588A2 (en) 2006-03-08
NO20055306D0 (no) 2005-11-10
US20050014224A1 (en) 2005-01-20
JP2007515942A (ja) 2007-06-21
JP4638876B2 (ja) 2011-02-23
JP2011055833A (ja) 2011-03-24
CO5680484A2 (es) 2006-09-29
NO20055306L (no) 2006-01-30
NZ543654A (en) 2009-05-31
WO2004107618A3 (en) 2005-02-10
WO2004107618A9 (en) 2005-06-09
KR20060052681A (ko) 2006-05-19
RU2005140279A (ru) 2006-06-10
US20100080809A1 (en) 2010-04-01
AU2004244626A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
BRPI0410785A (pt) molécula de ácido nucleico isolada, célula hospedeira, animal transgênico não humano, proteìna isolada, oligonucleotìdeo anti-sentido, molécula de sirna, anticorpo isolado, métodos de triagem quanto aos compostos de teste capazes de inibir, de intensificar ou imitar a interação do gitrl com o gitr, para diagnosticar doenças, para tratar um paciente em risco ou diagnosticado com uma doença, para induzir e para inibir a proliferação de uma população celular contendo células t efetoras, de bloquear a supressão e de supressão de uma população celular que inclua células t efetoras na presença de células t reguladoras cd4+cd25+, e para tratar uma doença, composição farmacêutica, e, adjuvante de vacina
Sun et al. The mechanosensitive Piezo1 channel is required for bone formation
Pollard et al. Mercury-induced inflammation and autoimmunity
Monshi et al. Human leukocyte antigen (HLA)‐B* 57: 01‐restricted activation of drug‐specific T cells provides the immunological basis for flucloxacillin‐induced liver injury
Lewis Jr et al. Genetic and cellular evidence of decreased inflammation associated with reduced incidence of posttraumatic arthritis in MRL/MpJ mice
Kokkola et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages
Cavalcante et al. Etiology of myasthenia gravis: innate immunity signature in pathological thymus
Jaing et al. Gene expression analysis of whole blood RNA from pigs infected with low and high pathogenic African swine fever viruses
Zhang et al. AIM2 facilitates the apoptotic DNA-induced systemic lupus erythematosus via arbitrating macrophage functional maturation
RU2596491C2 (ru) Способы и композиции для лечения персистирующих инфекций
Urbonaviciute et al. Toll‐like receptor 2 is required for autoantibody production and development of renal disease in pristane‐induced lupus
Zhang et al. Chemokine signaling pathway involved in CCL2 expression in patients with rheumatoid arthritis
Verma et al. Gene polymorphisms in the NALP3 inflammasome are associated with interleukin‐1 production and severe inflammation: relation to common inflammatory diseases?
Crowley et al. Matrix metalloproteinase-10 is a target of T and B cell responses that correlate with synovial pathology in patients with antibiotic-refractory Lyme arthritis
Bender et al. Btk inhibition treats TLR7/IFN driven murine lupus
Thibault et al. Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus
JP2011137838A (ja) 内因性のｍＲＮＡタンパク質（ｍＲＮＰ）複合体の単離および特徴付けの方法
Luong et al. Stimulation of TLR4 by recombinant HSP70 requires structural integrity of the HSP70 protein itself
Guo et al. Inflammasome assays in vitro and in mouse models
US20090048117A1 (en) Modulation of immune system function by modulation of polypeptide arginine methyltransferases
Li et al. Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis
WO2009097424A1 (en) Fstl-1 as a biomarker of inflammation
US7615380B2 (en) Methods for modulating an immune response by modulating KRC activity
Fouda et al. A fluorescence-based lymphocyte assay suitable for high-throughput screening of small molecules
Ding et al. Toll‐like receptor engagement stimulates anti‐snRNP autoreactive B cells for activation

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A E 7A ANUIDADES.

B08J Incorrect entry in the gazette republished [chapter 8.10 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. TEXTO CORRETO: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO(S) DESPACHO(S) 8.10 E 8.6 PUBLICADO(S) NA(S) RPI(S) 2132 DE 16/11/2011 E 2129 DE 25/10/2011, RESPECTIVAMENTE.